TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25923482
Drug: Casein 20
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein 20 g/day
Study: 8127888
Drug: Melatonin (0.1‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.1‐10 mg, orally)
Study: 324400
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg every 12 h for 5 days)
Study: 25947184
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (5 times a week for 2 weeks)
Study: 12616665
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) alone or in combination with didanosine
Study: 9089002
Drug: Mini 30
Normalized name: UltiCare Mini 30G 3/16 inch Safety Pen Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini 30 (0.03 mg levonorgestrel)
Study: 1345050
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive therapy
Study: 3009962
Drug: nabilone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabilone (2 X 2 mg/day)
Study: 3009962
Drug: alizapride (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: alizapride (3 X 150 mg/day)
Study: 23137509
Drug: Intramyocardial bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial bone marrow cell (BMC) injection (100 × 10^6 BMC)
Study: 23137509
Drug: Intramyocardial bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial bone marrow cell (BMC) injection
Study: 12219064
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3350 at 1 g/kg per day
Study: 1026547
Drug: 0-1% halcinonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-1% halcinonide cream (with neomycin and nystatin)
Study: 20223497
Drug: Intravenous taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous taurolidine in crystalloid cardioplegia
Study: 20223497
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion of normal saline in crystalloid cardioplegia
Study: 20223497
Drug: Intravenous taurolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous taurolidine in blood cardioplegia
Study: 20223497
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion of normal saline in blood cardioplegia
Study: 1748135
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg ER o.d.
Study: 1748135
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg o.d.
Study: 15906759
Drug: Physiological solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological solution (control)
Study: 15906759
Drug: Octreotide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (administered to 7 patients post-study)
Study: 12388617
Drug: Dopaminergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic therapy (dopamine-replete state)
Study: 12388617
Drug: Hypodopaminergic state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodopaminergic state (i.e., > or =12 hr after last dose of dopaminergic treatment)
Study: 8775804
Drug: Saquinavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir monotherapy
Study: 8775804
Drug: Saquinavir combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir combination therapy with zidovudine
Study: 8775804
Drug: Saquinavir combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir combination therapy with zidovudine and zalcitabine
Study: 8775804
Drug: Saquinavir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir at higher doses (2-4 times higher)
Study: 27868327
Drug: Doctor-patient communication
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor-patient communication with a focus on discussing medication themes and lifestyle treatment.
Study: 17110396
Drug: Both CC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CC and rFSH
Study: 9484914
Drug: Chemotherapy given
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy given prior to or simultaneously with definite radiotherapy
Study: 15018017
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin
Study: 12828803
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) for depression
Study: 11237928
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid (2 g daily)
Study: 11237928
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (4 g daily)
Study: 11237928
Drug: Quercetin‐3‐rutinoside (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin‐3‐rutinoside (440 mg daily)
Study: 11407649
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg sc)
Study: 8280556
Drug: Piroximone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroximone (loading dose of 0.5 mg kg‐1 followed by an infusion of 5 micrograms kg‐1 min‐1)
Study: 24917119
Drug: Grintuss® pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grintuss® pediatric syrup
Study: 22401329
Drug: Monthly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly group medical visits (GMVs)
Study: 16317218
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg IV plus dexamethasone 20 mg (group A)
Study: 16317218
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg IV plus dexamethasone 20 mg (group B)
Study: 8864768
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PHT and PB
Study: 8864768
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBZ and PB
Study: 8864768
Drug: Drug-free (DF)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free (DF)
Study: 6383763
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg dipyridamole intravenously
Study: 24475198
Drug: Active case
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active case detection method (children monitored actively, visited twice weekly, tympanic temperature measured, malaria rapid diagnostic test performed if fever present)
Study: 11697755
Drug: Intranasal lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal lorazepam (2 mg)
Study: 21837394
Drug: Buccal lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal lorazepam (2 mg)
Study: 15650833
Drug: Home-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based daily exercise therapy (20-min exercise program once per day for 8 weeks)
Study: 15650833
Drug: Home-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based daily exercise therapy
Study: 12815801
Drug: Oral antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamines and topical steroids
Study: 7728916
Drug: AVS plus
Normalized name: Sentry AV Ornacyn-Plus 29 MG Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVS plus intravenous immunoglobulin (IVIG)
Study: 23467275
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 μg/kg per day, six doses) plus standard therapy
Study: 3318896
Drug: Nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 10 mg ml‐1 (group N)
Study: 3318896
Drug: Buprenorphine 0.15
Normalized name: buprenorphine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.15 mg ml‐1 (group B)
Study: 29289540
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg/d
Study: 23805859
Drug: Naltrexone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 25 mg/day
Study: 19027483
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 intravenously every 3 weeks)
Study: 17329466
Drug: Risperidone (1.5-6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1.5-6.0 mg/day)
Study: 20205984
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isoflavones
Study: 11216491
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg and 40 mg isoflavones
Study: 27977721
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (100 mg QD) for 14 days
Study: 11476474
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy (SIT)
Study: 26901657
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive behavioral therapy
Study: 17178181
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg q.i.d. on days 1 and 2
Study: 19880464
Drug: Enriched Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched Supportive Therapy (EST)
Study: 3138681
Drug: misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol 400 micrograms twice daily for 28 days
Study: 3138681
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg twice daily for four weeks with misoprostol 400 micrograms twice daily during the second and third weeks
Study: 28372549
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (1.0 g over 10 doses)
Study: 12181401
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 400 mg daily
Study: 12181401
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 600 mg daily
Study: 8031206
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg/d, increased to 40 mg/d and 80 mg/d based on response)
Study: 8031206
Drug: Niacin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (1.5 g/d, increased to 3 g/d and 4.5 g/d based on response)
Study: 31091372
Drug: Dabigatran (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (150 mg or 110 mg twice daily)
Study: 29175902
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral aspirin daily for up to 24 weeks
Study: 23492458
Drug: Right-side stellate
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right-side stellate ganglion block (SGB) using 8 mL 0.75% ropivacaine for 4 times
Study: 16855454
Drug: Modafinil during
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil during open-label treatment
Study: 16855454
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of Modafinil during double-blind treatment phase
Study: 10837282
Drug: 5.1 g
Normalized name: POVIDONE-IODINE 5.1 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.1 g psyllium twice daily
Study: 31005929
Drug: Gut microbiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut microbiome transfer (28 capsules of frozen microbial suspension)
Study: 31005929
Drug: Placebo (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (28 capsules of saline)
Study: 22992309
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Laser, Sham laser, Needle)
Study: 20384520
Drug: CD34(+) cell
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34(+) cell therapy
Study: 16273791
Drug: TNF blocker
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNF blocker therapy
Study: 8738880
Drug: Oxytocin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (0.5 IU, intravenous infusion within 2.5 min via a forearm catheter)
Study: 2009998
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 1 mg/kg
Study: 2009998
Drug: MTX (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (1 mg/kg) systemic injection on days 3, 5, and 7 after local injection
Study: 2009998
Drug: Sulprostone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulprostone (500 micrograms) systemic injection on the 1st 2 postlocal injection days
Study: 27109624
Drug: Naltrexone (NTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (NTX; 25 mg OD for 2 days, then 50 mg OD for 3 days)
Study: 19212971
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for low panic-high worry and high panic-high worry sub-groups
Study: 19212971
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for low panic-low worry subjects
Study: 19212971
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for high worry subjects
Study: 31923099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dietary protein intake of 0.9 g/kg/day)
Study: 29449290
Drug: ReTrain intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ReTrain intervention (including an introductory one-to-one session, ten twice-weekly group classes, a closing one-to-one session, and three drop-in sessions over 3 months)
Study: 24346625
Drug: Further acupuncture
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further acupuncture treatment during the follow-up period
Study: 24346625
Drug: Not wanting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not wanting to use medications
Study: 24346625
Drug: Using additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using additional therapies
Study: 385025
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (6 mg piretanide, 9 mg piretanide, 1 mg bumetanide)
Study: 23827100
Drug: Prednisolone (PSL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (PSL, 1.5 mg/kg for 2-4 weeks and subsequently stepwise reduction)
Study: 23827100
Drug: Dexamethasone (HDD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (HDD, 40 mg/day, d1-4)
Study: 23827100
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus HDD (rituximab 100 mg on days 7, 14, 21, 28 and HDD)
Study: 15691867
Drug: l-NAME (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-NAME (180 µg.kg(‐1).h(‐1))
Study: 12162933
Drug: Inhibitors of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitors of cholesterol absorption, acyl coenzyme A‐cholesterol acyltransferase, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, liver X receptor agonists
Study: 7726492
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg every 12 h for five doses)
Study: 7726492
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg every 6 h for nine doses)
Study: 17100739
Drug: Vehicle with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle with 308-nm monochromatic excimer light (MEL) therapy
Study: 12385678
Drug: AMX/CA 2000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMX/CA 2000/125 mg bid
Study: 10385761
Drug: Alteplase (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (intravenous infusion of a total dose of 100 mg over a 2‐hour period, including an initial 10‐mg bolus)
Study: 2174446
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg per day for 3 weeks
Study: 26105170
Drug: Raltegravir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 800 mg twice daily initially then 400 mg twice daily after 4 weeks (arm 2)
Study: 24315882
Drug: Ramosetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron (5 μg oral, once daily for 12 weeks)
Study: 9846858
Drug: Sucrose polyester
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose polyester (60 mL)
Study: 8081594
Drug: Actiferrin Compositum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actiferrin Compositum (1 capsule per day from 36th week, increasing to 2 capsules per day until childbirth)
Study: 20306535
Drug: Garlic capsules
Normalized name: Garlic 500 MG Oral Capsule, Liquid Filled [GARLIC CAPSULES]
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic capsules (656 mg daily)
Study: 30582271
Drug: Valsartan/Amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine 80/5 mg
Study: 16154016
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg adding perindopril 4-8 mg as required
Study: 1416875
Drug: Isepamicin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin (7.5 mg/kg) with piperacillin (4 g every 12 h for four doses)
Study: 26414912
Drug: one tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet weekly (one/week)
Study: 26414912
Drug: one tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet twice weekly (two/week)
Study: 26414912
Drug: Steady-state daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state daily dosing serum TFV and PBMC TFV-DP
Study: 20940646
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (manual massage and compression)
Study: 12651168
Drug: Compression treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression treatment
Study: 11109969
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of recombinant follicle stimulating hormone (FSH) followed by highly purified urinary FSH
Study: 17924872
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of cinnamon (OGTT(cin))
Study: 17924872
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of cinnamon taken 12 h before (OGTT(cin12hpre))
Study: 9537699
Drug: Calcium-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-restricted diet (500 mg/day, oxalate-rich products discouraged, normalization of animal protein and sodium)
Study: 681526
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment strategy
Study: 30422156
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (arm A)
Study: 30422156
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cetuximab (arm B)
Study: 29051274
Drug: Immediate-release oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oral morphine
Study: 16514812
Drug: Captopril administration
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril administration
Study: 3061717
Drug: Frusemide injection
Normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frusemide injection and standing
Study: 24010577
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cobimetinib oral dose (tablets)
Study: 24010577
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabeprazole daily for 5 days prior to cobimetinib administration
Study: 2179550
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 mg/kg)
Study: 7191300
Drug: triamterene preparation
Normalized name: Triamterene
DrugBank: Triamterene (DB00384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamterene preparation 3
Study: 26010890
Drug: Full behavioural
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full behavioural activation treatment (ten sessions)
Study: 19052779
Drug: Outpatient cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient cognitive behavioural treatment (CBT)
Study: 16449106
Drug: Foley with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley with extra-amniotic saline infusion
Study: 15267006
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion with 300 ml saline during CM administration
Study: 15267006
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of at least 2,000 ml saline within 12 h before and after CM application
Study: 11687322
Drug: Course in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Course in psychosocial oncology for nurses, consisting of four 3-hour weekly lessons and follow-up discussions at termination and 5 months later.